Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
- OPACC
- Mar 28, 2022
- 1 min read
Adding the proteasome inhibitor bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
Comments